Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression

Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression

Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors. Although epigenome modulation provides a promising avenue in treating resistant cancer types, more studies are required to evaluate...

Full description

Bibliographic Details
Main Authors: Verona Buocikova, Silvia Tyciakova, Eleftherios Pilalis, Chara Mastrokalou, Maria Urbanova, Miroslava Matuskova, Lucia Demkova, Veronika Medova, Eleonora Marta Longhin, Elise Rundén-Pran, Maria Dusinska, Ivan Rios-Mondragon, Mihaela Roxana Cimpan, Alena Gabelova, Andrea Soltysova, Bozena Smolkova, Aristotelis Chatziioannou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
decitabine
DNA methylation
gene expression
deoxycytidine kinase
cytosine deaminase
whole-genome analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.991751/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.991751/full

Similar Items